CNS Pharmaceuticals, Inc. (CNSP)

Over the past six months, CNS Pharmaceuticals, Inc. stock price has experienced a significant decrease of -82.56%. More recently, over the last three months, the change has been -62.33%, and in the past month, the stock decreased by 16.36% as of November 21, 2025. The stock's 52-week high was $114.00 and its 52-week low was $4.93. As of November 21, 2025, the closing price was $6.90. The stock has shown volatility, with its share price being volatile over the past 3 months compared to the US market. Its weekly volatility has decreased from 18% to 11% over the past year, but it remains higher than 75% of US stocks. On November 13, 2025, a buy signal was issued from a pivot bottom point, and the stock has risen 4.50% since then. There is also a buy signal from the 3-month Moving Average Convergence Divergence (MACD). However, some negative signals from both short and long-term Moving Averages suggest a more negative near short-term forecast.

Information regarding demand seasonality for CNS Pharmaceuticals, Inc.'s products and services is not available in the provided search results. As a clinical-stage pharmaceutical company focused on developing treatments for severe medical conditions like brain cancer, demand for its potential products, once commercialized, would likely be driven by medical need rather than seasonal fluctuations. The company is currently in the research and development phase and has not reported any revenue, indicating that commercial sales and associated demand seasonality are not yet applicable.

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing anti-cancer drug candidates for brain and central nervous system tumors, operating within the Health Technology sector, specifically Biotechnology: Pharmaceutical Preparations. The company's primary focus is on glioblastoma multiforme (GBM), and its pipeline includes Berubicin and TPI 287, as well as CNS-12. Berubicin is a novel anthracycline that has shown promise in preclinical studies for its ability to cross the blood-brain barrier and kill tumor cells. TPI 287 is an abeotaxane that stabilizes microtubules and inhibits cell division, leading to cell death and has demonstrated an excellent safety profile and high tolerability.

CNS Pharmaceuticals, Inc. is headquartered in Houston, Texas, United States. The company has a potential international reach for its clinical trials, with a sub-licensee partner undertaking trials in Poland for Berubicin.

Information specifically detailing CNS Pharmaceuticals, Inc.'s brand reputation is not explicitly available in the provided search results. The company's focus on developing treatments for aggressive and incurable brain cancers like glioblastoma multiforme suggests a mission-driven approach that could positively influence its reputation within the medical community and patient advocacy groups. The company regularly reports financial results and provides corporate updates, which contributes to transparency.

CNS Pharmaceuticals, Inc. has a mix of institutional, retail, and individual investors. Approximately 14.02% of CNS Pharmaceuticals' stock is owned by institutional investors. Cortice Biosciences Inc. is the largest individual shareholder, owning 573,368 shares, representing 92.44% of the company. Insider sentiment for CNSP is positive, with 10 different insiders buying shares over the last year, totaling $253.3K in high-impact open-market purchases.